Liposomal NMN Superior to Regular NMN in Elevating NAD+ Levels
Aging is being redefined.
In 2022, the World Health Organization (WHO) introduced a dedicated code for "aging-related" conditions for the first time in the 11th Revision of the International Classification of Diseases (ICD-11). This signifies that the functional decline brought on by aging is no longer an irreversible law of nature, but a target that can be medically intervened and scientifically delayed.
In this battle against time, efficiently raising in vivo NAD+ (coenzyme I) levels and reactivating mitochondrial vitality stand at the center of global anti-aging research.
In February 2025, a double-blind, controlled clinical trial published in the international journal Annals of Clinical and Medical Case Reports provided a significant answer: Liposomal NMN is significantly more effective than regular NMN at increasing blood NAD+ concentrations.
As a global pioneer in full-enzymatic NMN technology, Bontac Bio has conducted a deep breakdown of this study. Below, we explain in the most direct terms what these data points truly mean.
The study enrolled 15 healthy male subjects aged 40 and older, who were randomly divided into three groups for a uniform 4-week daily intervention:
Group A (Placebo Control): Took 4 g of maltodextrin daily, containing no NMN.
Group B (Liposomal NMN): Supplemented daily with 350 mg of liposome-encapsulated NMN.
Group C (Regular Free NMN): Supplemented daily with 350 mg of conventional free NMN powder.
Liposomal NMN vs. Placebo: p = 0.000, showing a massive difference in efficacy.
Liposomal NMN vs. Regular NMN: p = 0.001, demonstrating a decisive lead in performance.
Regular NMN vs. Placebo: p = 0.545, showing almost no improvement effect.
With multiple steps, ingredient degradation, and energy consumption, it is like taking a subway with two transfers.
No enzymatic breakdown required, no transporters needed, and energy-conserving—it works like taking an express direct line. Researchers explicitly pointed out that this is the key reason Liposomal NMN generates higher levels of NAD+.
Bontac's Deep Breakdown: Regular NMN is constrained by two major loss checkpoints—"CD73 enzymatic breakdown + NR transport"—causing large amounts of active ingredients to be lost along the way. Liposomal technology directly bypasses these two hurdles, maximizing the retention of intracellular NMN raw material to continuously and efficiently synthesize NAD+.
As age advances, human NAD+ levels continuously decline, leading to:
Decreased organ function
Increased risk of age-related diseases
Simultaneously, NAD+ activates SIRT1—known as the "longevity gene"—regulating glucose and lipid metabolism, enhancing immune function, and inhibiting age-related inflammation. Because of this, NAD+ is regarded by the global scientific community as an important biomarker for measuring mitochondrial activity and biological age.
Elevating NAD+ levels is not merely an increase in numerical value; it represents a return to a youthful cellular state. How to make the elevation of NAD+ more efficient and direct is precisely the core challenge that Bontac Bio's Liposomal NMN technology aims to solve.
Leveraging over a decade of synthetic biology R&D accumulation and industrialization experience, Bontac has also taken the lead in achieving mass production in liposomal delivery technology, extending its technical advantage from the "raw material end" to the "delivery end":
Fundamental Raw Material Guarantee: Self-developed full-enzymatic production process, seven-step Bonpure® purification, stable NMN purity ≥ 99.9%, certified by international safety standards such as GRAS and FSSC22000, with no chemical synthesis residues.
Bontac Bio will continue to deepen R&D in delivery technology to provide global partners with more efficient and reliable NAD+ anti-aging raw material solutions.
Reference：
Kawakami S, Maeda Y, Fukuzawa Y. Intervention Study Comparing Blood NAD⁺ Concentrations with Liposomal and Non-Liposomal Nicotinamide Mononucleotide. Ann Clin Med Case Rep. 2025;14(11):1-12.
In 2022, the World Health Organization (WHO) introduced a dedicated code for "aging-related" conditions for the first time in the 11th Revision of the International Classification of Diseases (ICD-11). This signifies that the functional decline brought on by aging is no longer an irreversible law of nature, but a target that can be medically intervened and scientifically delayed.
In this battle against time, efficiently raising in vivo NAD+ (coenzyme I) levels and reactivating mitochondrial vitality stand at the center of global anti-aging research.
In February 2025, a double-blind, controlled clinical trial published in the international journal Annals of Clinical and Medical Case Reports provided a significant answer: Liposomal NMN is significantly more effective than regular NMN at increasing blood NAD+ concentrations.
As a global pioneer in full-enzymatic NMN technology, Bontac Bio has conducted a deep breakdown of this study. Below, we explain in the most direct terms what these data points truly mean.
PART 01
Clinical Proof: At Equivalent Doses, Liposomal NMN Drives an 83.6% Leap in NAD+ Levels
Conducted jointly by Kiryu University and Maeda Clinic in Japan, this randomized, double-blind, controlled clinical trial is an authoritative study evaluating the bioavailability of different NMN formulations.The study enrolled 15 healthy male subjects aged 40 and older, who were randomly divided into three groups for a uniform 4-week daily intervention:
Group A (Placebo Control): Took 4 g of maltodextrin daily, containing no NMN.
Group B (Liposomal NMN): Supplemented daily with 350 mg of liposome-encapsulated NMN.
Group C (Regular Free NMN): Supplemented daily with 350 mg of conventional free NMN powder.
Core Measurement Data
Blood cell NAD+ concentrations were measured after 4 consecutive weeks of supplementation: The baseline mean for the Liposomal NMN group was 28.6 μM, which rose to 52.5 μM after 4 weeks—an overall increase of 83.6%.
Statistical Significance (p < 0.05 indicates a statistically significant difference)
:Liposomal NMN vs. Placebo: p = 0.000, showing a massive difference in efficacy.
Liposomal NMN vs. Regular NMN: p = 0.001, demonstrating a decisive lead in performance.
Regular NMN vs. Placebo: p = 0.545, showing almost no improvement effect.
Bontac's Professional Analysis
Clear conclusions can be drawn from the clinical data: At an equivalent intake dose of 350 mg, regular free NMN is limited by absorption pathway losses in the gut and fails to effectively elevate blood NAD+ levels in humans. In contrast, liposomal delivery technology dramatically improves cellular utilization of NMN, outperforming conventional formulations across the board in raising NAD+.Additional Long-Term Observation Results
When re-tested 4 weeks after all subjects stopped supplementation, NAD+ concentrations in the Liposomal NMN group remained significantly higher than baseline levels prior to the trial (p = 0.043). This breaks the pain point of regular NMN—where levels drop back immediately upon discontinuation—and highlights why Liposomal NMN can substantially raise in vivo NAD+ concentrations with sustained long-term biological effects.PART 02
Why Is Liposomal NMN More Effective?
Regular NMN's Absorption Pathway: Circuitous and Energy-Consuming
Regular NMN cannot be absorbed directly in the human intestine. It must first be dephosphorylated by the CD73 enzyme into nicotinamide riboside (NR), which then enters cells via Equilibrative Nucleoside Transporters (ENTs).
With multiple steps, ingredient degradation, and energy consumption, it is like taking a subway with two transfers.
Liposomal NMN's Absorption Pathway: Direct Step
Liposomes are spherical vesicles made of a phospholipid bilayer, highly similar in structure to human cell membranes. Through membrane fusion mechanisms, Liposomal NMN can deliver intact NMN directly into the interior of cells.
No enzymatic breakdown required, no transporters needed, and energy-conserving—it works like taking an express direct line. Researchers explicitly pointed out that this is the key reason Liposomal NMN generates higher levels of NAD+.
Bontac's Deep Breakdown: Regular NMN is constrained by two major loss checkpoints—"CD73 enzymatic breakdown + NR transport"—causing large amounts of active ingredients to be lost along the way. Liposomal technology directly bypasses these two hurdles, maximizing the retention of intracellular NMN raw material to continuously and efficiently synthesize NAD+.
PART 03
NAD+: The "Gold Standard" in Anti-Aging
If a cell is compared to an engine, NAD+ is the fuel that keeps it running. NAD+ is the core coenzyme of mitochondrial energy metabolism, directly involved in the tricarboxylic acid (TCA) cycle and the respiratory chain.As age advances, human NAD+ levels continuously decline, leading to:
Decline in mitochondrial function
Energy metabolism disorders Decreased organ function
Increased risk of age-related diseases
Simultaneously, NAD+ activates SIRT1—known as the "longevity gene"—regulating glucose and lipid metabolism, enhancing immune function, and inhibiting age-related inflammation. Because of this, NAD+ is regarded by the global scientific community as an important biomarker for measuring mitochondrial activity and biological age.
Elevating NAD+ levels is not merely an increase in numerical value; it represents a return to a youthful cellular state. How to make the elevation of NAD+ more efficient and direct is precisely the core challenge that Bontac Bio's Liposomal NMN technology aims to solve.
PART 04
Bontac Bio: NMN Pioneer, Leading Mass Production of Liposomal Delivery Technology
As the world's first national-level specialized and sophisticated "Little Giant" enterprise to achieve large-scale mass production of NMN, Bontac Bio holds 25 NMN-related invention patents and serves as a core raw material supplier to numerous global health brands and research institutions.Leveraging over a decade of synthetic biology R&D accumulation and industrialization experience, Bontac has also taken the lead in achieving mass production in liposomal delivery technology, extending its technical advantage from the "raw material end" to the "delivery end":
Fundamental Raw Material Guarantee: Self-developed full-enzymatic production process, seven-step Bonpure® purification, stable NMN purity ≥ 99.9%, certified by international safety standards such as GRAS and FSSC22000, with no chemical synthesis residues.
Mass Production & Delivery of Liposomal NMN: Self-developed high-compatibility lecithin nano-encapsulation process, now scaled for industrial production, effectively addressing the absorption loss pain point of regular NMN. It currently supplies multiple global brand clients with differentiated, high-bioavailability raw material formulations.
Industry-Academia-Research Validation: Continuously partnering with domestic and international medical institutions to carry out human clinical trials, supporting product iterations with real clinical data. The Japanese double-blind clinical study published in February 2025 fully validates the significant advantage of liposomal delivery in elevating NAD+—aligning closely with the technological direction used in Bontac Bio's Liposomal NMN raw materials and further strengthening our confidence in sustained investment in the liposomal delivery platform. Bontac Bio will continue to deepen R&D in delivery technology to provide global partners with more efficient and reliable NAD+ anti-aging raw material solutions.
Reference：
Kawakami S, Maeda Y, Fukuzawa Y. Intervention Study Comparing Blood NAD⁺ Concentrations with Liposomal and Non-Liposomal Nicotinamide Mononucleotide. Ann Clin Med Case Rep. 2025;14(11):1-12.
